纳米靶向技术用于乳腺癌免疫治疗的最新进展
杭州医学院, 医学影像学院, 浙江杭州 310059
| 摘 要： | 免疫治疗作为一种革命性的癌症治疗方法，通过增强自身免疫应答，阻碍免疫抑制作用，提高抗肿瘤反应，为乳腺癌治疗提供了有效选择。然而，由于肿瘤的复杂性以及肿瘤免疫抑制微环境等问题，严重限制了免疫治疗的发展。近年来，纳米技术给药物研究和治疗带来了新的可能性。本文主要探讨了乳腺癌免疫治疗的新进展及其与纳米药物靶向作用系统的结合。通过利用纳米技术制备的纳米药物，可以实现对肿瘤微环境的精确调控，实现定向局部免疫调节，从而提高免疫治疗效果。纳米药物靶向作用系统旨在将药物直接输送到肿瘤部位，减少对正常组织和细胞的损害，降低药物副作用。此外，纳米药物还能够与其他治疗手段（如化疗、放疗等）联合使用，发挥协同作用，进一步提高乳腺癌治疗效果。本文综述了乳腺癌免疫治疗中纳米药物靶向作用系统的研究进展，以及其在改善肿瘤微环境和联合疗法方面的应用潜力，并展望了未来的机遇与挑战。 |
| 关 键 词： | 乳腺癌; 免疫治疗; 纳米药物; 靶向; 联合疗法 |
| DOI： | 10.57237/j.mrf.2023.03.005 |
View:
Downloads:
收稿日期: 2023-05-26
接受日期: 2023-07-06
在线出版日期: 2023-07-24
Recent Progress of Nanotargeted Immunotherapy for Breast Cancer
School of Medical Imaging, Hangzhou Medical College, Hangzhou 310059, China
| Abstract: | Immunotherapy, as a revolutionary cancer treatment approach, offers an effective option for breast cancer treatment by enhancing the body's immune response, inhibiting immunosuppression, and improving anti-tumor reactions. However, the development of immunotherapy is severely limited due to the complexity of tumors and tumor immunosuppressive microenvironments. In recent years, nanotechnology has introduced new possibilities in drug research and treatment. This article mainly explores the latest advancements in breast cancer immunotherapy and its combination with nanoparticle drug targeting systems. Utilizing nanoparticles prepared through nanotechnology, precise regulation of the tumor microenvironment can be achieved, resulting in targeted local immune modulation and improved immunotherapy effects. The nanoparticle drug targeting system aims to deliver drugs directly to the tumor site, reducing damage to normal tissues and cells and decreasing drug side effects. Additionally, nanoparticle drugs can be used in conjunction with other treatments (such as chemotherapy and radiotherapy) to produce synergistic effects and further improve breast cancer treatment outcomes. This review summarizes the research progress of nanoparticle drug targeting systems in breast cancer immunotherapy, as well as their potential applications in improving the tumor microenvironment and combined therapies. It also looks forward to future opportunities and challenges. |
| Keywords: | Breast Cancer; Immunotherapy; Nanomedicine; Targeted; Combination Therapy |
参考文献
| [1] | W. H. Organization, 2020. https://www.who.int/news/item/03-02-2021-breast-cancer-now-most-common-form-of-cancer-who-taking-action. |
| [2] | Coffey J C, Wang J H, Smith M, et al. Excisional surgery for cancer cure: Therapy at a cost. Lancet Oncol, 2003, 4: 760–768. |
| [3] | Chabner B A, Roberts Jr T G. Chemotherapy and the war on cancer. Nat Rev Cancer, 2005, 5: 65–72. |
| [4] | Baskar R, Lee K A, Yeo R, et al. Cancer and radiation therapy: Current advances and future directions. Int J Med Sci, 2012, 9: 193–199. |
| [5] | Taube J M, Klein A, Brahmer J R, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res, 2014, 20: 5064–5074. |
| [6] | Lee Ventola, C. Cancer immunotherapy, part 3: Challenges and future trends. Pharm. Therp. 2017, 42, 514–521. |
| [7] | Sugie, T. Immunotherapy for metastatic breast cancer. Chin. Clin. Oncol. 2018, 7, 7. |
| [8] | Maeda, H.; Fang, J.; Inutsuka, T.; Kitamoto, Y. Vascular permeability enhancement in solid tumor: Various factors, mechanisms involved and its implications. Int. Immunopharmacol. 2003, 3, 319–328. |
| [9] | Maeda, H. The enhanced permeability and retention (EPR) effect in tumor vasculature: The key role of tumor-selective macromolecular drug targeting. Adv. Enzyme Regul. 2001, 41, 189–207. |
| [10] | Iyer, A. K.; Khaled, G.; Fang, J.; Maeda, H. Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov. Today 2006, 11, 812–818. |
| [11] | Alba Navarro-Ocón, J. L. B. A. and A. S. Granados-Principal, Nanomedicine as a promising tool to overcome immune escape in breast cancer. pharmaceutics, 2022. |
| [12] | Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment [J]. Cancer Cell, 2012, 21 (3): 309-322. |
| [13] | Meads MB, Gatenby RA, Dalton WS. Environmentmediated drug resistance: a major contributor to minimal residual disease [J]. Nat Rev Cancer, 2009, 9 (9): 665-674. |
| [14] | Shen, L., et al., Local Blockade of Interleukin 10 and C-X-C Motif Chemokine Ligand 12 with Nano-Delivery Promotes Antitumor Response in Murine Cancers. ACS Nano, 2018. 12 (10): p. 9830-9841. |
| [15] | Zhou W, Fong Miranda Y, Min Y, et al. Cancer-secreted miR-105 destroys vascular endothelial barriers to promote metastasis [J]. Cancer Cell, 2014, 25 (4): 501-515. 10.1016/j.ccr.2014.03.007. |
| [16] | Massagué J. TGFβ in cancer. Cell, 2008, 134: 215-230. |
| [17] | Neuzillet C, Tijeras-Raballand A, Cohen R, et al. Targeting the TGFβ pathway for cancer therapy. Pharmacol Ther, 2015, 147: 22–31. |
| [18] | Fan Y, He S. The characteristics of tumor microenvironment in triple negative breast cancer [J]. Cancer Management and Research, 2022: 1-17. |
| [19] | Wormann, S. M.; Diakopoulos, K. N.; Lesina, M.; Algul, H., The Immune Network in Pancreatic Cancer Development and Progression. Oncogene 2014, 33, 2956-2967. |
| [20] | Fortis, C.; Foppoli, M.; Gianotti, L.; Galli, L.; Citterio, G.; Consogno, G.; Gentilini, O.; Braga, M., Increased Interleukin-10 Serum Levels in Patients with Solid Tumours. Cancer Lett 1996, 104, 1-5. |
| [21] | Shen, L.; Li, J.; Liu, Q.; Song, W.; Zhang, X.; Tiruthani, K.; Hu, H.; Das, M.; Goodwin, T. J.; Liu, R.; et al. Local Blockade of Interleukin 10 and C-X-C Motif Chemokine Ligand 12 with Nano-Delivery Promotes Antitumor Response in Murine Cancers. ACS Nano 2018, 2, 9830–9841. |
| [22] | Buchsbaum, R. J.; Oh, S. Y. Breast Cancer-Associated Fibroblasts: Where We Are and Where We Need to Go. Cancers 2016, 8, 19. |
| [23] | Bochet, L.; Lehuédé, C.; Dauvillier, S.; Wang, Y. Y.; Dirat, B.; Laurent, V.; Dray, C.; Guiet, R.; Maridonneau-Parini, I.; Le Gonidec, S.; et al. Adipocyte-derived fibroblasts promote tumor progression and contribute to the desmoplastic reaction in breast cancer. Cancer Res. 2013, 73, 5657–5668. |
| [24] | Raz, Y.; Cohen, N.; Shani, O.; Bell, R. E.; Novitskiy, S. V.; Abramovitz, L.; Levy, C.; Milyavsky, M.; Leider-Trejo, L.; Moses, H. L.; et al. Bone marrow-derived fibroblasts are a functionally distinct stromal cell population in breast cancer. J. Exp. Med. 2018, 215, 3075–3093. |
| [25] | Mollah, F. and P. Varamini, Overcoming Therapy Resistance and Relapse in TNBC: Emerging Technologies to Target Breast Cancer-Associated Fibroblasts. Biomedicines, 2021. 9 (12): p. 1921. |
| [26] | Sitia, L., et al., Selective Targeting of Cancer-Associated Fibroblasts by Engineered H-Ferritin Nanocages Loaded with Navitoclax. Cells, 2021. 10 (2): p. 328. |
| [27] | A. H. Zahalka, P. S. Frenette, Nerves in cancer. Nat. Rev. Cancer 20, 143–157 (2020). |
| [28] | Q. Zhao, Y. Yang, X. Liang, G. Du, L. Liu, L. Lu, J. Dong, H. Han, G. Zhang, The clinicopathological significance of neurogenesis in breast cancer. BMC Cancer 14, 484 (2014). |
| [29] | M. Mancino, E. Ametller, P. Gascon, V. Almendro, The neuronal influence on tumor progression. Biochim. Biophys. Acta 1816, 105–118 (2011). |
| [30] | C. Liebig, G. Ayala, J. A. Wilks, D. H. Berger, D. Albo, Perineural invasion in cancer: A review of the literature. Cancer 115, 3379–3391 (2009). |
| [31] | Kaduri, M., et al., Targeting neurons in the tumor microenvironment with bupivacaine nanoparticles reduces breast cancer progression and metastases. Science Advances, 2021. 7 (41): p. eabj5435-eabj5435. |
| [32] | Sheen MR, Lizotte PH, Toraya-Brown S, Fiering S. Stimulating antitumor immunity with nanoparticles. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2014; 6: 496–505. |
| [33] | Lizotte, P. H.; Wen, A. M.; Sheen, M. R.; Fields, J.; Rojanasopondist, P.; Steinmetz, N. F.; Fiering, S. In situ vaccination with cowpea mosaic virus nanoparticles suppresses metastatic cancer. Nat. Nanotechnol. 2016, 11, 295–303. |
| [34] | Zhu, L.; Kalimuthu, S.; Oh, J. M.; Gangadaran, P.; Baek, S. H.; Jeong, S. Y.; Lee, S. W.; Lee, J.; Ahn, B. C. Enhancement of antitumor. potency of extracellular vesicles derived from natural killer cells by IL-15 priming. Biomaterials 2019, 190–191, 38–50. |
| [35] | Alizadeh D, Zhang L, Hwang J, Schluep T, Badie B. Nanomedicine. |
| [36] | Jackson H, Muhammad O, Daneshvar H, Nelms J, Popescu A, Vogelbaum MA, Bruchez M, Toms SA. Neurosurgery. 2007; 60: 524. |
| [37] | Lewis C, Leek R, Harris A, McGee J. J Leuk Bio. 1995; 57: 747. |
| [38] | Dreaden, E., et al. (2012). "Small molecule-gold nanorod conjugates selectively target and induce macrophage cytotoxicity towards breast cancer cells." 8 (18): 2819-2822. |
| [39] | Kopecka, J.; Porto, S.; Lusa, S.; Gazzano, E.; Salzano, G.; Pinzòn-Daza, M. L.; Giordano, A.; Desiderio, V.; Ghigo, D.; De Rosa, G.; et al. Zoledronic acid-encapsulating self-assembling nanoparticles and doxorubicin: A combinatorial approach to overcome simultaneously chemoresistance and immunoresistance in breast tumors. Oncotarget 2016, 7, 20753–20772. |
| [40] | BRAHMER J R, TYKODI S S, CHOW L Q, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer [J]. N Engl J Med, 2012, 366 (26): 2455-2465. |
| [41] | DONG H, STROME S E, SALOMAO D R, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion [J]. Nat Med, 2002, 8 (8): 793-800. |
| [42] | DE MAESENEER D J, DELAFONTAINE B, ROTTEY S. Checkpoint inhibition: new treatment options in urologic cancer [J]. Acta Clin Belg, 2017, 72 (1): 24-28. |
| [43] | BLANK C, BROWN I, PETERSON A C, et al. PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells [J]. Cancer Res, 2004, 64 (3): 1140-1145. |
| [44] | 李瑛, 范忠义, 尤文叶, et al. PD-1/PD-L1 信号通路在肿瘤免疫逃逸中的作用及临床意义 [J]. 解放军医学院学报, 2015, (07): 762-765. |
| [45] | PHILIPS G K, ATKINS M. Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies [J]. International Immunology, 2015, 27 (1): 39-46. |
| [46] | 邓颖莎. 人PD-1胞外段表达及其纳米抗体的筛选 [D]. 广东:暨南大学, 2019. |
| [47] | Miao, L.; Wang, Y.; Lin, C. M.; Xiong, Y.; Chen, N.; Zhang, L.; Kim, W. Y.; Huang, L. Nanoparticle modulation of the tumor microenvironment enhances therapeutic efficacy of cisplatin. J. Control. Release 2015, 217, 27-41. |
| [48] | Liu X, Zhou M, Mei L, et al. Key roles of necroptotic factors in promoting tumor growth [J]. Oncotarget, 2016, 7 (16): 22219-22233. |
| [49] | Zielinska E, Zauszkiewicz-Pawlak A, Wojcik M, et al. Silver nanoparticles of different sizes induce a mixed type of programmed cell death in human pancreatic ductal adenocarcinoma [J]. Oncotarget, 2018, 9 (4): 4675-4697. |
| [50] | 陈文娟. 基于聚合物载体的乳腺癌疫苗的设计和实验研究[D]. 北京: 北京协和医学院, 2020. |
| [51] | Yang, B., Jeang, J., Yang, A., Wu, T. C., & Hung, C. F. (2014). DNA vaccine for cancer immunotherapy. Hum Vaccin Immunother, 10 (11), 3153-3164. |
| [52] | Norell H, Poschke I, Charo J, et al. Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trial. J Transl Med 2010; 8: 53. |
| [53] | Mittendorf E. A., Clifton G. T., Holmes J. P., Schneble E., Van Echo D., Ponniah S., Peoples G. E. Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients [J]. Ann Oncol, 2014, 25 (9): 1735-1742. |
| [54] | Qian CY, Liu XL, Xu Q, et al. Recent progress on the versatility of virus-like particles [J]. Vaccines, 2020, 8: 14. |
| [55] | Palladini A, Thrane S, Janitzek CM, et al. Virus-like particle dis- play of HER2 induces potent anti-cancer responses [J]. Oncoim-munology, 2018, 7: e1408749. |
| [56] | Campbell, K., Young, V. L., Donaldson, B. C., Woodall, M. J., Shields, N. J., Walker, G. F., Young, S. L. (2021). Delivering Two Tumour Antigens Survivin and Mucin-1 on Virus-Like Particles Enhances Anti-Tumour Immune Responses. Vaccines (Basel), 9 (5). |
| [57] | Criscitiello C, Corti C, Pravettoni G, Curigliano G. Managing side effects of immune checkpoint inhibitors in breast cancer. Crit Rev Oncol Hematol 2021; 162: 103354. |
| [58] | Curigliano G, Bagnardi V, Ghioni M, et al. Expression of tumor-associated antigens in breast cancer subtypes. Breast 2020; 49: 202e9. |
| [59] | Belli C, Trapani D, Viale G, et al. Targeting the microenvironment in solid tumors. Cancer Treat Rev 2018; 65: 22e32. |
| [60] | Bryson, P. D., Han, X., Truong, N., & Wang, P. (2017). Breast cancer vaccines delivered by dendritic cell-targeted lentivectors induce potent antitumor immune responses and protect mice from mammary tumor growth. Vaccine, 35 (43), 5842-5849. |
| [61] | LI M, GAO Y, YUAN Y, et al. One-step formulation of targeted aggregation-induced emission dots for image-guided photodynamic therapy of cholangiocarcinom [a J]. ACS Nano, 2017, 11 (4): 3922-3932. |
| [62] | CHENG Y, CHENG H, JIANG C, et al. Perfluorocarbon nanoparticles enhance reactive oxygen levels and tumour growth inhibition in photodynamic therap [y J]. Nat Commun, 2015, 6: 8785-8792. |
| [63] | Chen X, Liu Y, Bu W. Sci Sin-Chim, 2020, 50: 159-172. |
| [64] | LUONGO M, BRIGIDA A L, MASCOLO L, et al. Possible therapeutic effects of ozone mixture on hypoxia in tumor developmen [t J]. Anticancer Res, 2017, 37 (2): 425-436. |
| [65] | ZHANG R, SONG X, LIANG C, et al. Catalase-loaded cisplatinprodrug-constructed liposomes to overcome tumor hypoxia for enhanced chemo-radiotherapy of cance [r J]. Biomaterials, 2017, 138: 13-21. |
| [66] | Tang Z, Liu Y, He M, Bu W. Angew Chem Int Ed, 2019, 58: 946-956. |
| [67] | Tang Z, Zhao P, Wang H, Liu Y, Bu W. Chem Rev, 2021, 121: 1981-2019. |
| [68] | Ranji-Burachaloo H, Gurr PA, Dunstan DE, Qiao GG.ACS Nano, 2018, 12: 11819-11837. |
| [69] | Huai Y, Hossen MN, Wilhelm S, Bhattacharya R, Mukherjee P. Bioconj Chem, 2019, 30: 2247-2263. |
| [70] | Huang Y, Ren J, Qu X. Chem Rev, 2019, 119: 4357-4412. |
| [71] | Yang Y, Zeng W, Huang P, Zeng X, Mei L. View, 2021, 2: 20200042888. |
| [72] | Liu J, Wu M, Pan Y, Duan Y, Dong Z, Chao Y, Liu Z, Liu B. Adv Funct Mater, 2020, 30: 1908865. |
| [73] | Liu Y, Wu J, Jin Y, Zhen W, Wang Y, Liu J, Jin L, Zhang S, Zhao Y, Song S, Yang Y, Zhang H. Adv Funct Mater, 2019, 29: 1904678. |
| [74] | Chen Y, Li ZH, Pan P, Hu JJ, Cheng SX, Zhang XZ. Adv Mater, 2020, 32: 2001452. |
| [75] | Kim J, Cho HR, Jeon H, Kim D, Song C, Lee N, Choi SH, Hyeon T. J Am Chem Soc, 2017, 139: 10992-10995. |
| [76] | Lin LS, Song J, Song L, Ke K, Liu Y, Zhou Z, Shen Z, Li J, Yang Z, Tang W, Niu G, Yang HH, Chen X. Angew Chem Int Ed, 2018, 57: 4902 -4906. |
| [77] | Wang Z, Li Z, Sun Z, Wang S, Ali Z, Zhu S, Liu S, Ren Q, Sheng F, Wang B, Hou Y. Sci Adv, 2020, 6: eabc8733. |
| [78] | Dong S, Dong Y, Jia T, Liu S, Liu J, Yang D, He F, Gai S, Yang P, Lin J. Adv Mater, 2020, 32: 2002439. |
| [79] | Li S, Shang L, Xu B, Wang S, Gu K, Wu Q, Sun Y, Zhang Q, Yang H, Zhang F, Gu L, Zhang T, Liu H. Angew Chem Int Ed, 2019, 58: 12624 -12631. |
| [80] | Ma B, Wang S, Liu F, Zhang S, Duan J, Li Z, Kong Y, Sang Y, Liu H, Bu W, Li L. J Am Chem Soc, 2019, 141: 849-857. |
| [81] | 孙思佳, 吴頔, 张贾鹤, 等. 超小型锰掺杂金纳米簇及微环境响应的肿瘤可视化诊疗 [J]. 中国科学（化学）, 2021, 51 (9): 1259-1268. |
| [82] | Jordan A, Scholz R, Wust P, et al. Effects of magnetic flu— id hyperthermia (MFH) on C3 H mammary carcinoma in vivo [J]. Int J Hyperthermia, 1997, 13 (6): 587-605. |
| [83] | Harrington KJ, et al. Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes [J]. Clin Cancer Res. 2001; 7: 243-254. |
| [84] | Koukourakis MI, et al. High intratumoural accumulation of stealth liposomal doxorubicin (Caelyx) in glioblastomas and in metastatic brain tumours [J]. Br J Cancer. 2000; 83: 1281-1286. |
| [85] | Lee H, et al. A gradient-loadable 64Cu-chelator for quantifying tumor deposition kinetics of nanoliposomal therapeutics by positron emission tomography [J]. Nanomedicine. 2015; 11: 155-165. |
